title: Rheumatoid arthritis and the era of biologic therapy.
abstract: Biologic disease modifying anti-rheumatic drugs have transformed the management of rheumatoid arthritis (RA) since their introduction into clinical practice over a decade ago. Following large-scale clinical trials, a number of biologics, with different mechanisms of action, have been licensed for the condition. In this review, we will summarise the current evidence for biologic use in RA with an emphasis on their efficacy and tolerability. In addition, we will provide a commentary on the current limitations and unmet needs in this area and discuss the future of biologic intervention.
authors.affiliation: School of Clinical Medicine, University of Cambridge, Cambridge, UK. anshuman.malaviya@addenbrookes.nhs.uk
authors.forename: Anshuman P
authors.initials: AP
authors.lastname: Malaviya
authors.forename: Andrew J K
authors.initials: AJ
authors.lastname: Ostör
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D017410:Practice Guidelines as Topic; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000093242:Interleukin-6 Inhibitors; D015850:Interleukin-6
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007136:Immunoglobulins; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C508600:IL6 protein, human; D015850:Interleukin-6